Electra Therapeutics announced its Q3 2026 financial results, highlighting a $23.9 million net loss and $402.5 million in cash post-IPO. The company is advancing its lead drug ipsoprubart in global trials for secondary hemophagocytic lymphohistiocytosis (sHLH) with enrollment expected to complete in late 2027. Ipsoprubart is also being tested in T/NK cell malignancies, with initial data due in the second half of 2027. Additionally, ELA822 is in Phase 1 trials for chronic immune diseases, with data and patient trials planned for 2027. The $350 million IPO funds these developments, supporting operations through 2029.
Electra Therapeutics' third quarter 2026 financial results provide context for the health sector's performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 23 rose and 124 fell. Notable movers include MRNA (Moderna, Inc.) at USD 230.95 with a 1-day change of -7.13% and a typical hold time of 58 days, Butterfly Network Inc. (BFLY) at USD 6.64 down 7.00%, and Recursion Pharmaceuticals Inc. (RXRX) at USD 3.34 down 6.96% with balanced buy/sell order activity.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
